Theravance Biopharma, Inc. Payments to Acquire Debt Securities, Available-for-sale
Theravance Biopharma, Inc. (TBPH) reported Payments to Acquire Debt Securities, Available-for-sale of $145.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $101.90M, a 80.12% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $43.41M, a 2105.64% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $64.93M, a 72.13% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $124.75M, a 177.94% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $248.22M, a 76.36% increase from fiscal 2024.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $140.74M, a 4.62% increase from fiscal 2023.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $134.53M, a 30.43% increase from fiscal 2022.
- Theravance Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $103.14M, a 34.84% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $101.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $145.31M 10-Q · filed 2026-08-11 | $210.24M derived: sum of 3 quarters · filed 2026-08-11 | $334.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $43.41M 10-Q · filed 2026-05-07 | $108.34M derived: sum of 2 quarters · filed 2026-05-07 | $233.08M derived: sum of 3 quarters · filed 2026-05-07 | $289.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $64.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $189.68M derived: sum of 2 quarters · filed 2026-03-23 | $246.25M derived: sum of 3 quarters · filed 2026-08-11 | $248.22M 10-K · filed 2026-03-23 |
| 2025-09-30 | $124.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $181.32M derived: sum of 2 quarters · filed 2026-08-11 | $183.29M 10-Q · filed 2025-11-12 | $221.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $56.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $58.54M 10-Q · filed 2026-08-11 | $96.26M derived: sum of 3 quarters · filed 2026-08-11 | $141.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.97M 10-Q · filed 2026-05-07 | $39.69M derived: sum of 2 quarters · filed 2026-05-07 | $84.57M derived: sum of 3 quarters · filed 2026-05-07 | $115.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $37.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $82.60M derived: sum of 2 quarters · filed 2026-03-23 | $113.84M derived: sum of 3 quarters · filed 2026-03-23 | $140.74M 10-K · filed 2026-03-23 |
| 2024-09-30 | $44.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $76.12M derived: sum of 2 quarters · filed 2025-11-12 | $103.02M 10-Q · filed 2025-11-12 | $103.02M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $31.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $58.14M 10-Q · filed 2025-08-13 | $58.14M derived: sum of 3 quarters · filed 2025-08-13 | $58.14M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $26.90M 10-Q · filed 2025-05-12 | $26.90M derived: sum of 2 quarters · filed 2025-05-12 | $26.90M derived: sum of 3 quarters · filed 2025-05-12 | $26.90M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $1.00K derived: sum of 3 quarters · filed 2025-03-07 | $134.53M 10-K · filed 2025-03-07 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.00K derived: sum of 2 quarters · filed 2024-11-14 | $134.53M 10-Q · filed 2024-11-14 | $144.42M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $134.53M 10-Q · filed 2024-08-08 | $144.42M derived: sum of 3 quarters · filed 2024-08-08 | $183.92M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $134.53M 10-Q · filed 2024-05-15 | $144.42M derived: sum of 2 quarters · filed 2024-05-15 | $183.91M derived: sum of 3 quarters · filed 2024-05-15 | $219.50M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $49.38M derived: sum of 2 quarters · filed 2024-03-01 | $84.97M derived: sum of 3 quarters · filed 2024-03-01 | $103.14M 10-K · filed 2024-03-01 |
| 2022-09-30 | $39.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $75.09M derived: sum of 2 quarters · filed 2023-11-09 | $93.26M 10-Q · filed 2023-11-09 | $146.79M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $35.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $53.76M 10-Q · filed 2023-08-09 | $107.29M derived: sum of 3 quarters · filed 2023-08-09 | $172.05M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $18.17M 10-Q · filed 2023-05-10 | $71.70M derived: sum of 2 quarters · filed 2023-05-10 | $136.47M derived: sum of 3 quarters · filed 2023-05-10 | $176.44M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $53.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $118.29M derived: sum of 2 quarters · filed 2023-03-01 | $158.27M derived: sum of 3 quarters · filed 2023-03-01 | $158.31M 10-K · filed 2023-03-01 |
| 2021-09-30 | $64.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $104.74M derived: sum of 2 quarters · filed 2022-11-09 | $104.77M 10-Q · filed 2022-11-09 | $169.21M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $39.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $40.01M 10-Q · filed 2022-08-08 | $104.44M derived: sum of 3 quarters · filed 2023-03-01 | $161.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $36.00K 10-Q · filed 2022-05-06 | $64.47M derived: sum of 2 quarters · filed 2023-03-01 | $121.53M derived: sum of 3 quarters · filed 2023-03-01 | $337.25M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $64.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $121.49M derived: sum of 2 quarters · filed 2023-03-01 | $337.21M derived: sum of 3 quarters · filed 2023-03-01 | $401.99M 10-K · filed 2023-03-01 |
| 2020-09-30 | $57.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $272.78M derived: sum of 2 quarters · filed 2021-11-08 | $337.56M 10-Q · filed 2021-11-08 | $395.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $215.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $280.50M 10-Q · filed 2021-08-05 | $337.98M derived: sum of 3 quarters · filed 2022-02-28 | $496.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $64.78M 10-Q · filed 2021-05-06 | $122.26M derived: sum of 2 quarters · filed 2022-02-28 | $280.65M derived: sum of 3 quarters · filed 2022-02-28 | $340.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $57.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $215.87M derived: sum of 2 quarters · filed 2022-02-28 | $275.76M derived: sum of 3 quarters · filed 2022-02-28 | $423.90M 10-K · filed 2022-02-28 |
| 2019-09-30 | $158.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $218.27M derived: sum of 2 quarters · filed 2020-11-09 | $366.41M 10-Q · filed 2020-11-09 | $383.26M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $59.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $208.03M 10-Q · filed 2020-08-10 | $224.88M derived: sum of 3 quarters · filed 2021-02-26 | $289.38M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $148.14M 10-Q · filed 2020-05-08 | $164.99M derived: sum of 2 quarters · filed 2021-02-26 | $229.49M derived: sum of 3 quarters · filed 2021-02-26 | $276.56M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $16.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $81.35M derived: sum of 2 quarters · filed 2021-02-26 | $128.42M derived: sum of 3 quarters · filed 2021-02-26 | $183.26M 10-K · filed 2021-02-26 |
| 2018-09-30 | $64.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $111.57M derived: sum of 2 quarters · filed 2019-11-08 | $166.41M 10-Q · filed 2019-11-08 | $169.38M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $47.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $101.91M 10-Q · filed 2019-08-05 | $104.88M derived: sum of 3 quarters · filed 2020-02-27 | $158.71M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $54.84M 10-Q · filed 2019-05-10 | $57.81M derived: sum of 2 quarters · filed 2020-02-27 | $111.64M derived: sum of 3 quarters · filed 2020-02-27 | $184.41M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $56.80M derived: sum of 2 quarters · filed 2020-02-27 | $129.57M derived: sum of 3 quarters · filed 2020-02-27 | $288.79M 10-K · filed 2020-02-27 |
| 2017-09-30 | $53.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $126.60M derived: sum of 2 quarters · filed 2018-11-08 | $285.82M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $72.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $231.99M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $159.22M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $237.57M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |